Market Overview

Top 4 NYSE Stocks In The Biotechnology Industry With The Highest Revenue Estimates

Share:
Related CRL
Earnings Scheduled For May 10, 2018
Benzinga's Top Upgrades, Downgrades For April 20, 2018
Related EBS
Emergent Biosolutions' Stock Run Can't Continue Forever, Wells Fargo Says In Downgrade
Benzinga's Top Upgrades, Downgrades For April 25, 2018
Emergent Biosolutions Earns Relative Strength Rating Upgrade (Investor's Business Daily)

Below are the top biotechnology stocks on the NYSE in terms of revenue estimate for the current year.

Analysts expect Charles River Laboratories International (NYSE: CRL) to post revenue of $1.14 billion for the year ending December, 2012. Charles River Laboratories' trailing-twelve-month ROE is 17.83%.

Emergent BioSolutions (NYSE: EBS) is expected to report revenue of $286.38 million for the year ending December, 2012. Emergent BioSolutions' PEG ratio is 0.72.

Cambrex (NYSE: CBM) is likely to post revenue of $274.60 million in the year ending December, 2012. Cambrex's trailing-twelve-month operating margin is 12.83%.

ShangPharma (NYSE: SHP) may report revenue of $132.94 million in the year ending December, 2012. ShangPharma had $34.74 million in total cash for the recent quarter.

Posted-In: Biotechnology Industry Highest Revenue Estimates NYSETrading Ideas

 

Related Articles (CBM + CRL)

View Comments and Join the Discussion!